文献速递头颈与中枢神经肿瘤

预处理EB病毒DNA筛选的低危局部晚期鼻咽癌减强度放化疗:一项II期随机非劣效性试验

Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial.
PubMed 文献 · J Clin Oncol · 2022-01-06

本II期随机非劣效性试验纳入332例预处理EB病毒DNA<4000拷贝/mL的低危局部晚期鼻咽癌患者,1:1随机接受2周期或3周期同步顺铂(DDP)100 mg/m2放化疗。中位随访37.7个月,3年无进展生存率两组分别为88.0%与90.4%,差异2.4%(95%CI -4.3至9.1,非劣效性P=.014),达到非劣效;3周期组3-4级黏膜炎、低钠血症和皮炎显著更多,总体毒性负担更重。

要点

  • 低危LA-NPC(预处理EBV DNA<4000拷贝/mL)中,2周期同步DDP 100 mg/m2的3年PFS非劣效于3周期。
  • 3年PFS:2周期组88.0% vs 3周期组90.4%,差异2.4%(95%CI -4.3至9.1,非劣效性P=.014)。
  • 3周期组3-4级黏膜炎41例(24.8%)vs 25例(15.1%),低钠血症26例(15.8%)vs 14例(8.4%),皮炎9例(5.5%)vs 2例(1.2%)。

核心结论

  • 调强放疗联合2周期同步100 mg/m2 DDP可作为低危LA-NPC患者的一种替代治疗选择。

研究设计与样本

  • 开放标签、II期、随机、对照非劣效性试验,纳入332例预处理EBV DNA<4000拷贝/mL的低危LA-NPC患者,1:1随机接受2周期或3周期同步DDP为基础的放化疗,主要终点为3年无进展生存(PFS)。

主要发现

  • 中位随访37.7个月,3年PFS率2周期组88.0% vs 3周期组90.4%,差异2.4%(95%CI -4.3至9.1,非劣效性P=.014)。
  • 两组在PFS、总生存以及局部区域复发和远处转移的累积发生率方面均无差异。
  • 3周期组3-4级黏膜炎41例(24.8%)vs 2周期组25例(15.1%),低钠血症26例(15.8%)vs 14例(8.4%),皮炎9例(5.5%)vs 2例(1.2%)。
  • 总体全级别和3-4级毒性负担3周期组更重(T评分:全级别12.33 vs 10.57,P<.001;3-4级1.76 vs 1.44,P=.05)。
  • 3周期组全级别听力损伤、口干和皮肤纤维化更多,长期生活质量受损更明显。

临床怎么用

  • 作者认为,调强放疗联合2周期同步100 mg/m2 DDP可作为低危LA-NPC患者的一种替代治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Cumulative doses of 200 mg/m2 for concurrent cisplatin (DDP) were indicated by retrospective studies as sufficient in conferring survival benefit for locoregionally advanced nasopharyngeal carcinoma (LA-NPC). We performed an open-label, phase II, randomized, controlled trial to test the noninferiority of a two-cycle 100 mg/m2 concurrent DDP regimen over three-cycle in patients with low-risk LA-NPC with pretreatment Epstein-Barr virus DNA levels < 4,000 copies/mL. PATIENTS AND METHODS: Eligible patients were randomly assigned 1:1 to receive two cycles or three cycles concurrent DDP-based chemoradiotherapy. The primary end point was 3-year progression-free survival (PFS). The secondary end points included overall survival, distant metastasis-free survival, locoregional relapse-free survival, etc. RESULTS: Between September 2016 and October 2018, 332 patients were enrolled, with 166 in each arm. After a median follow-up of 37.7 months, the estimated 3-year PFS rates were 88.0% in the two-cycle group and 90.4% in the three-cycle group, with a difference of 2.4% (95% CI, -4.3 to 9.1, Pnoninferiority = .014). No differences were observed between groups in terms of PFS, overall survival, and the cumulative incidences of locoregional relapse and distant metastasis. Patients in the three-cycle group developed significantly more grade 3-4 mucositis (41 [24.8%] v 25 [15.1%]), hyponatremia (26 [15.8%] v 14 [8.4%]), and dermatitis (9 [5.5%] v 2 [1.2%]). The overall all-grade and grade 3-4 toxicity burdens were heavier in three-cycle group (T-scores, 12.33 v 10.57, P < .001 for all grades; 1.76 v 1.44, P = .05 for grade 3-4). Patients in the three-cycle group also showed more all-grade hearing impairment, dry mouth and skin fibrosis, and impaired long-term quality of life. CONCLUSION: Intensity-modulated radiotherapy plus two cycles of concurrent 100 mg/m2 DDP could be an alternative treatment option for patients with low-risk LA-NPC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Li XY, Luo DH, Guo L, et al. Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial. J Clin Oncol. 2022. PMID: 34990291. doi:10.1200/JCO.21.01467

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。